The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.
